§ EQUITY
USD

NGEN

NERVGEN PHARMA CORP
USD
LAST
n/a
n/aPREV CLOSE · n/a
§ 01 · PRICE
Price action
1D5D1M6MYTD1YMAX

§ 03 · SIGNAL STACK · WHAT THE INPUTS SAY

13F FLOW
44 increased/new, 7 decreased/exited (13F)
AC 13F Analysis
ANALYST
7 buy, 1 hold, 0 sell
Finnhub
§ 05 · WHO OWNS IT
Top institutional holders
All holders →
FundShares% portΔ Q/Q
PFG Investments, LLC201K0.0%n/a
Bank of America Corp201K0.0%n/a
Marshall Wace LLP200K0.0%n/a
ROYAL BANK OF CANADA172K0.0%n/a
Integrated Wealth Concepts LLC87K0.0%n/a
VALLEY FORGE INVESTMENT CONSULTANTS INC ADV78K0.1%n/a
◇ AC INTELLIGENCE

Top institutional owners for NGEN as of the most recent 13F reporting period (Q1 2026 · Period ended Mar 31). Δ Q/Q reflects share-count change vs. the prior filing — positive green means adding, negative red means trimming. Cross-reference with the ownership-mix bars below to see which strategy cohort is driving the flow.

§ 06 · WHO OWNS IT · BY STRATEGY

OTHER52.7% · 33 holders
DEALER / BANK33.2% · 9 holders
SYSTEMATIC / QUANT12.0% · 2 holders
INCOME / DEFENSIVE2.2% · 1 holder
◇ AC INTELLIGENCE

Ownership mix by behavioral cohort. Top bars indicate which style of capital dominates the float — passive indexing, quality compounders, dealer/bank, systematic quant, etc. Big quality-compounder share means concentrated active conviction; heavy passive share means flows are dictated by index rebalances, not fundamentals.

§ 07 · INSIDER ACTIVITY · LAST 180 DAYS

NO INSIDER FILINGS
◇ AC INTELLIGENCE

No Form 4 filings on record for NGEN in the last 180 days.

§ 08 · COVERAGE · OUR RECENT NOTES

No notes mention NGEN yet.